ADMA/SDMA may be measured in individuals with multiple risk factors for the development of CVD.
One of the earliest manifestations of endothelial dysfunction is nitric oxide (NO) deficiency, which promotes atherosclerosis. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), its structural isomer, are metabolites of L-arginine, an amino acid that is catalyzed to L-citrulline and NO by nitric oxide synthase (NOS).
Both ADMA and SDMA have distinct pathophysiologies and manifestations. ADMA is a competitive inhibitor of NOS thereby reducing NO production and promoting endothelial dysfunction. SDMA also interferes with NO production, but does so indirectly by reducing the cellular availability of arginine. ADMA is primarily cleared through enzymatic degradation in the bloodstream and its presence identifies subclinical cardiovascular disease (CVD). Conversely, SDMA is primarily excreted in the urine and identifies reduced renal function.
Interpretation:
ADMA: Low // SDMA: Low
Normal endothelial function Med High Low
ADMA: Med / High // SDMA: Low
Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD
ADMA: Low // SDMA: High
Reduced renal function
ADMA: Med / High // SDMA: High
- Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD
- Reduced renal function
References:
American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S125–S143. https://doi.org/10.2337/dc22-S009
Understand and improve your laboratory results with our health dashboard.
Upload your lab reports and get your interpretation today.
Our technology helps to understand, combine, track, organize, and act on your medical lab test results.
Elevated levels of ADMA may identify:
- Endothelial dysfunction
- Pre-diabetes/diabetes
- Subclinical cardiovascular disease
Higher levels of ADMA are associated with a 1.40x increased risk of CVD and coronary heart disease, as well as a 1.60x increased risk of stroke, in a general population.
-- Elevated ADMA levels are associated with the presence of hypertension, insulin resistance, and hyperlipidemia.
-- Elevated ADMA levels are associated with subclinical atherosclerosis:
-- Individuals with established coronary artery disease and elevated ADMA levels have more than twice the risk for adverse events (myocardial infarction, stroke) than those with normal ADMA levels.
Treatment Considerations:
These treatment considerations are for educational purposes only. Specific treatment plans should be provided and reviewed by the treating practitioner.
Assess lifestyle habits.
- Consider diet, exercise, and weight reduction efforts, if appropriate.
Assess LDL-C levels.
- If not at an optimal level, consider lipid-lowering therapies described in the National Cholesterol Education Program/Adult Treatment Panel III (NCEP ATP III) Guidelines. [L]
Assess insulin sensitivity.
- If not at an optimal level, consider insulin-sensitizing therapies described in the American Diabetes Association guidelines for the management of pre-diabetes/ diabetes. [L]
Assess blood pressure.
- If not at an optimal level, consider initiating, or titrating, antihypertensive therapy.
- Consider L-arginine or L-citrulline supplementation to enhance NO production, and to improve vasodilation and vascular tone.
Assess the presence of coronary artery disease (CAD) with imaging techniques, such as carotid intima-media thickness (CIMT) testing or coronary artery calcium (CAC) scoring.
Assess clotting risk.
- Consider antiplatelet therapy if history of CAD (i.e., myocardial infarction or revascularization) and/or cerebrovascular disease (i.e., transient ischemic attack or stroke).
Assess renal function.
- If SDMA levels are not optimal, consider further assessment and treatment considerations for kidney disease, as outlined in the National Kidney Foundation guidelines. [L]
Interpret Your Lab Results
Upload your lab report, and we'll interpret and provide you with recommendations today.
Get StartedOur specialized data entry service is designed to seamlessly integrate your laboratory results into your private dashboard. Just send in your lab test results—whether it's an image or a file—and our skilled data entry team will handle the rest. We accommodate various file formats like PDFs, JPGs, and Excel.
The first report is complimentary. After that, the data entry service is priced at $15 per report, unless it's part of your subscribed plan. It's an ideal solution whether you have numerous reports to upload or if your schedule doesn't permit self-data entry.
We strive to make the data entry process easy for you. Whether by offering dozens of templates to choose from that pre-populate the most popular laboratory panels or by giving you instant feedback on the entered values. Our data entry forms are an easy, fast, and convenient way to enter the reports yourself. There is no limit on how many lab reports you can upload.
Personal plans
track personal results
Professional Plan
track multiple client's results
$15/month
$250/once
own it for life
$45/month
for health professionals
Personal Account
$15/month
for personal lab results
$250/once
own it for life
Level up your lab report analysis with our Pro plan, built for health practitioners like you.
Health Business Account
$45/month
Unlock additional Pro plans when you sign up.
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.